🔎 Trials Near Me

Akèy › Kansè Endomèt › Ohio

Etid klinik pou Kansè Endomèt nan Ohio

50 etid pou Kansè Endomèt ap chèche patisipan nan sit nan Ohio.

Vil nan Ohio

Tèks ofisyèl etid la (Anglè)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • OhioHealth O'Bleness Hospital, Athens
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • ak 39 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  • Cleveland Clinic Foundation, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Oct 2, 2026 · NCT05950464

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • OhioHealth O'Bleness Hospital, Athens
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • Aultman Health Foundation, Canton
  • ak 19 plis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 2, 2026 · NCT07198074

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Cleveland Clinic, Cleveland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05051722

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • Miami Valley Hospital South, Centerville
  • Geauga Hospital, Chardon
  • ak 8 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 28, 2026 · NCT05112601

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The Ohio State University Wexner Medical Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • The Ohio State University Wexner Medical Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 24, 2026 · NCT04590326

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • Geauga Hospital, Chardon
  • Case Western Reserve University, Cleveland
  • ak 4 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 24, 2026 · NCT05640999

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Cincinnati
  • Research Site, Columbus
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • Miami Valley Hospital South ( Site 6014), Centerville
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001), Kettering
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT06952504

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • Miami Valley Hospital South, Centerville
  • Ohio State University, Hilliard
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT06340568

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

  • GSK Investigational Site, Canton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07213609

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Cleveland Clinic, Cleveland
  • Toledo Clinic Cancer Center, Toledo
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • University of Cincinnati Medical Center, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 9, 2026 · NCT07166094

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The Ohio State University, Columbus
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Columbus
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 21, 2026 · NCT05797168

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati Cancer Center, Cincinnati
  • Ohio State University, Hilliard
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Aug 21, 2026 · NCT05548296

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Maumee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • Ohio State University Wexner Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07470853

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
  • Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • University Hospital - Cleveland Medical Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Oncology Hematology Care Primary, Cincinnati
  • Taylor Cancer Research Center, Maumee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Cincinnati
  • Research Site, Cleveland
  • Research Site, Cleveland
  • ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 29, 2026 · NCT07044336

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

  • University of Cincinnati Physicians Group, LLC, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 28, 2026 · NCT07022483

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 304, Centerville
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Jul 16, 2026 · NCT06906341

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • UH Cleveland Medical Center, Cleveland
  • Stefanie Spielman Comprehensive Breast Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139

Integrated Cancer Repository for Cancer Research

  • Aultman Alliance Community Hospital, Alliance
  • Aultman Hospital, Canton
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.